Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Actinomycetota

ABSTRACT: Actinomycetota Transcriptome or Gene expression

PROVIDER: PRJNA1061271 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27823300_1.fastq.gz	Fastqsanger.gz
	SRR27823300_2.fastq.gz	Fastqsanger.gz
	SRR27823247_1.fastq.gz	Fastqsanger.gz
	SRR27823247_2.fastq.gz	Fastqsanger.gz
	SRR27823248_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 108

Similar Datasets

Actinomycetota

Project description:Actinomycetota Raw sequence reads

| PRJNA734473 | ENA

Actinomycetota

Project description:Actinomycetota Raw sequence reads

| PRJNA726020 | ENA

Actinomycetota bacterium

Project description:Actinomycetota bacterium overview

| PRJNA1104359 | ENA

Actinomycetota bacterium isolate:MAG

Project description:Actinomycetota bacterium isolate:MAG Genome sequencing

| PRJNA1103325 | ENA

Actinomycetota bacterium isolate:csdadc MAG8

Project description:Actinomycetota bacterium isolate:csdadc MAG8 Genome sequencing

| PRJNA1103324 | ENA

Biomarks of Resistance to Cetuximab in Colorectal Cancer

Project description:Interventions: A group:Before using cetuximab;B group:After progression of disease:no Primary outcome(s): KRAS gene sequence;NRAS gene sequence;BRAF gene sequence;PIK3CA gene sequence;EGFR gene sequence;EGFR gene copy numbers;EGFR expression;Her2 expression;c-Met expression;PTEN expression Study Design: historical control

| 2671639 | ecrin-mdr-crc

Antifungal mechanism of volatile compounds emitted by Actinomycetota Paenarthrobacter ureafaciens from a disease-suppressive soil on Saccharomyces cerevisiae.

Project description:Antifungal mechanism of volatile compounds emitted by Actinomycetota Paenarthrobacter ureafaciens from a disease-suppressive soil on Saccharomyces cerevisiae.

| PRJNA1001987 | ENA

Bioinformatic identification of ClpI, a distinct class of Clp unfoldases in Actinomycetota.

Project description:All clades of bacteria possess Hsp100/Clp family unfoldase enzymes that contribute to aspects of protein quality control. In Actinomycetota, these include ClpB, which functions as an independent chaperone and disaggregase, and ClpC, which cooperates with the ClpP1P2 peptidase to carry out regulated proteolysis of client proteins. We initially sought to algorithmically catalog Clp unfoldase orthologs from Actinomycetota into ClpB and ClpC categories. In the process, we uncovered a phylogenetically distinct third group of double-ringed Clp enzymes, which we term ClpI. ClpI enzymes are architecturally similar to ClpB and ClpC, with intact ATPase modules and motifs associated with substrate unfolding and translation. While ClpI possess an M-domain similar in length to that of ClpC, its N-terminal domain is more variable than the strongly conserved N-terminal domain of ClpC. Surprisingly, ClpI sequences are divisible into sub-classes that either possess or lack the LGF-motifs required for stable assembly with ClpP1P2, suggesting distinct cellular roles. The presence of ClpI enzymes likely provides bacteria with expanded complexity and regulatory control over protein quality control programs, supplementing the conserved roles of ClpB and ClpC.

| S-EPMC10149685 | biostudies-literature

iChip-Inspired Isolation, Bioactivities and Dereplication of <i>Actinomycetota</i> from Portuguese Beach Sediments.

Project description:Oceans hold a stunning number of unique microorganisms, which remain unstudied by culture-dependent methods due to failures in establishing the right conditions for these organisms to grow. In this work, an isolation effort inspired by the iChip was performed using marine sediments from Memoria beach, Portugal. The isolates obtained were identified by 16S rRNA gene analysis, fingerprinted using BOX-PCR and ERIC-PCR, searched for the putative presence of secondary metabolism genes associated with polyketide synthase I (PKS-I) and non-ribosomal peptide synthetases (NRPS), screened for antimicrobial activity against Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 29213, and had bioactive extracts dereplicated by LC/HRMS. Of the 158 isolated strains, 96 were affiliated with the phylum Actinomycetota, PKS-I and NRPS genes were detected in 53 actinomycetotal strains, and 11 proved to be bioactive (10 against E. coli, 1 against S. aureus and 1 against both pathogens). Further bioactivities were explored using an "one strain many compounds" approach, with six strains showing continued bioactivity and one showing a novel one. Extract dereplication showed the presence of several known bioactive molecules and potential novel ones in the bioactive extracts. These results indicate the use of the bacteria isolated here as sources of new bioactive natural products.

| S-EPMC9319460 | biostudies-literature

TR study of ‘multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer&quot

Project description:Primary outcome(s): Cancer-related gene alteration, expression of protein, and expression of RNA

| 2645675 | ecrin-mdr-crc